The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.
The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.
The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.
After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.
After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
The FDA has approved Baqsimi nasal powder, the first glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection.
The FDA has approved Baqsimi nasal powder, the first glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection.
